Time to treatment response in first-episode schizophrenia: Should acute treatment trials last several months?

Journal of Clinical Psychiatry

Volumn 72, Issue 12, 2011, Pages 1691-1696

  Gallego, Juan A ^a   Robinson, Delbert G ^a,b,c   Sevy, Serge M ^a,c   Napolitano, Barbara ^b   McCormack, Joanne ^a   Lesser, Martin L ^b,c,d   Kane, John M ^a,b,c  

^a ZUCKER HILLSIDE HOSPITAL   (United States)

^b FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH   (United States)

^c ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^d WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

OLANZAPINE; RISPERIDONE;

ADULT; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG RESPONSE; FEMALE; FIRST EPISODE SCHIZOPHRENIA; HUMAN; MAJOR CLINICAL STUDY; MALE; POSITIVE SYNDROME; PREDICTION; PREDICTIVE VALUE; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SCHIZOPHRENIFORM DISORDER; SENSITIVITY AND SPECIFICITY; UNITED STATES;

EID: 84555220522     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.10m06349     Document Type: Article

References (30)

1. Lieberman J, Jody D, Geisler S, et al. Time course and biologic correlates of treatment response in first-episode schizophrenia. Arch Gen Psychiatry. 1993;50(5):369-376. (Pubitemid 23143126)
2. Emsley R, Rabinowitz J, Medori R. Time course for antipsychotic treatment response in first-episode schizophrenia. Am J Psychiatry. 2006;163(4):743-745. (Pubitemid 44464590)
3. Kay SR, Fiszbein A, Opler LA. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13(2):261-276. (Pubitemid 18039085)
4. Perkins D, Lieberman J, Gu H, et al. HGDH Research Group. Predictors of antipsychotic treatment response in patients with first-episode schizophrenia, schizoaffective and schizophreniform disorders. Br J Psychiatry. 2004;185(1):18-24. (Pubitemid 38951625)
5. McEvoy JP, Lieberman JA, Perkins DO, et al. Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind 52-week comparison. Am J Psychiatry. 2007;164(7):1050-1060. (Pubitemid 47121394)
6. Lieberman JA, Phillips M, Gu H, et al. Atypical and conventional antipsychotic drugs in treatment-naive first-episode schizophrenia: a 52-week randomized trial of clozapine vs chlorpromazine. Neuropsychopharmacology. 2003;28(5):995-1003.
7. Robinson DG, Woerner MG, Napolitano B, et al. Randomized comparison of olanzapine versus risperidone for the treatment of first-episode schizophrenia: 4-month outcomes. Am J Psychiatry. 2006;163(12):2096-2102. (Pubitemid 46114229)
8. Lieberman JA, Tollefson G, Tohen M, et al. HGDH Study Group. Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol. Am J Psychiatry. 2003;160(8):1396-1404. (Pubitemid 41070913)
9. Kahn RS, Fleischhacker WW, Boter H, et al.; EUFEST study group. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet. 2008;371(9618):1085-1097. (Pubitemid 351418005)
10. Emsley R, Oosthuizen PP, Kidd M, et al. Remission in first-episode psychosis: predictor variables and symptom improvement patterns. J Clin Psychiatry. 2006;67(11):1707-1712. (Pubitemid 44955150)
11. Lin CH, Chou LS, Lin CH, et al. Early prediction of clinical response in schizophrenia patients receiving the atypical antipsychotic zotepine. J Clin Psychiatry. 2007;68(10):1522-1527. (Pubitemid 350073399)
12. Chen L, Ascher-Svanum H, Stauffer V, et al. Optimal thresholds of early response to atypical antipsychotics: application of signal detection methods. Schizophr Res. 2009;113(1):34-40.
13. Ascher-Svanum H, Nyhuis AW, Faries DE, et al. Clinical, functional, and economic ramifications of early nonresponse to antipsychotics in the naturalistic treatment of schizophrenia. Schizophr Bull. 2008;34(6):1163-1171.
14. Kinon BJ, Chen L, Ascher-Svanum H, et al. Predicting response to atypical antipsychotics based on early response in the treatment of schizophrenia. Schizophr Res. 2008;102(1-3):230-240.
15. Correll CU, Malhotra AK, Kaushik S, et al. Early prediction of antipsychotic response in schizophrenia. Am J Psychiatry. 2003;160(11):2063- 2065. (Pubitemid 39619650)
16. Leucht S, Shamsi SA, Busch R, et al. Predicting antipsychotic drug response - replication and extension to six weeks in an international olanzapine study. Schizophr Res. 2008;101(1-3):312-319.
17. Leucht S, Busch R, Kissling W, et al. Early prediction of antipsychotic nonresponse among patients with schizophrenia. J Clin Psychiatry. 2007;68(3):352-360. (Pubitemid 46506798)
18. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Washington, DC: American Psychiatric Association; 1994.
19. Endicott J, Spitzer RL. A diagnostic interview: the schedule for affective disorders and schizophrenia. Arch Gen Psychiatry. 1978;35(7):837-844. (Pubitemid 9076798)
20. Robinson D, Woerner M, Schooler N. Intervention research in psychosis: issues related to clinical assessment. Schizophr Bull. 2000;26(3):551-556.
21. Guy W. ECDEU Assessment Manual for Psychopharmacology. US Dept Health, Education, & Welfare publication (ADM) 73-338. Rockville, MD: National Institute of Mental Health; 1976:217-222.
22. Endicott J, Spitzer RL, Fleiss JL, et al. The global assessment scale: a procedure for measuring overall severity of psychiatric disturbance. Arch Gen Psychiatry. 1976;33(6):766-771.
23. Andreasen NC, Carpenter WT Jr, Kane JM, et al. Remission in schizophrenia: proposed criteria and rationale for consensus. Am J Psychiatry. 2005;162(3):441-449. (Pubitemid 40343909)
24. Salimi K, Jarskog LF, Lieberman JA. Antipsychotic drugs for first-episode schizophrenia: a comparative review. CNS Drugs. 2009;23(10):837-855.
25. Ram R, Bromet EJ, Eaton WW, et al. The natural course of schizophrenia: a review of first-admission studies. Schizophr Bull. 1992;18(2):185-207.
26. Lieberman JA, Alvir JM, Woerner M, et al. Prospective study of psychobiology in first-episode schizophrenia at Hillside Hospital. Schizophr Bull. 1992;18(3):351-371.
27. Kinon BJ, Chen L, Ascher-Svanum H, et al. Early response to antipsychotic drug therapy as a clinical marker of subsequent response in the treatment of schizophrenia. Neuropsychopharmacology. 2010;35(2): 581-590.
28. Lencz T, Robinson DG, Xu K, et al. DRD2 promoter region variation as a predictor of sustained response to antipsychotic medication in firstepisode schizophrenia patients. Am J Psychiatry. 2006;163(3):529-531. (Pubitemid 44469398)
29. Garner B, Berger GE, Nicolo JP, et al. Pituitary volume and early treatment response in drug-naïve first-episode psychosis patients. Schizophr Res. 2009;113(1):65-71.
30. Merlo MC, Kleinlogel H, Koukkou M. Differences in the EEG profiles of early and late responders to antipsychotic treatment in first-episode, drug-naive psychotic patients. Schizophr Res. 1998;30(3):221-228. (Pubitemid 28189554)